Tomophase Corporation is a private company founded
in 2003 with a goal of providing innovative solutions
for unmet medical needs through the use of light-based imaging and therapy.
Many major advances in medicine have been marked by the introduction of new medical imaging tools, such as computed tomography, magnetic resonance imaging, and positron emission tomography. We believe that a new breakthrough, one of similar magnitude, is now within our reach — the use of light in guiding us to new ways of diagnosing diseases and improving our lives.
Tomophase has developed and patented technology in
the field of optical coherence tomography (OCT)
which is capable of delivering high quality, high resolution cross-sectional tissue images in real-time. With
the Tomophase Optical Coherence Tomography Imaging System (OCTIS™,) tissue structure can be observed up to 2-3 mm below the surface with remarkable clarity and without biopsy or the use of radiation, UV light or image contrast agents.
Our first proposed application of this innovative
technology is in pulmonary medicine for the tomographic imaging of
airways and pulmonary tissue. We believe the Tomophase OCT imaging
system will allow clinicians, for the first time, to visualize such
microanatomic features as airway epithelia, mucosa, smooth
muscle layer both in-vivo and in-situ. This
may facilitate or improve many of the interventional procedures
and therapeutic approaches in pulmonology. Further development may also lead to tools for improving the management of lung cancer as well as applications in other fields of medicine.
We at Tomophase are dedicated to fulfilling light’s diagnostic potential through continued innovations,
skilled management, close alliances with the medical community, and excellence in engineering.